The increased need for AST infrastructure drives the antimicrobial susceptibility testing market
The Antimicrobial Susceptibility Testing Market is estimated to be valued at US$ 3751.4 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Antimicrobial susceptibility testing (AST) is a laboratory technique used to determine the sensitivity of a microbial pathogen to different antimicrobial drugs. AST identifies pathogens in a clinical sample and determines which antimicrobial drugs are most likely to be effective for treatment. The results help clinicians prescribe appropriate antimicrobial therapy and reduce the spread of drug-resistant organisms. AST also monitors the emergence of resistance in pathogens over time allowing updates to treatment guidelines based on changing susceptibility patterns.
Market Dynamics:
The increasing prevalence of drug-resistant infections is a major driver of the antimicrobial susceptibility testing market. According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security, and development today. The emergence of multidrug-resistant strains of tuberculosis, malaria, HIV, and other pathogens has complicated treatment and lowered recovery rates. This has driven the need for improved AST to optimize treatment and minimize unnecessary antibiotic use which further fuels resistance.
Another driver is the implementation of guidelines mandating AST for certain pathogens and clinical situations. For example, U.S. Joint Commission on Accreditation of Healthcare Organizations requires facilities to have policies addressing periodic antimicrobial testing of all clinically relevant microorganisms to monitor local resistance trends. Compliance with such regulations increases demand for AST products, services, and testing capacity.
Segment Analysis
The antimicrobial susceptibility testing market is dominated by the instruments segment which accounts for more than 50% of the overall market share. This is because instruments such as automated systems aids in faster and accurate testing as compared to manual test methods. The instruments segment is further divided into automated laboratory instruments and consumables. Among these, automated laboratory instruments sub-segment dominates due to growing demand for automated testing in clinical diagnostic laboratories to quickly detect microbial sensitivity or resistance to antimicrobial medicines.
PEST Analysis
Political: Stringent regulatory guidelines by governments and healthcare agencies to prevent antimicrobial resistance is boosting the adoption of AST.
Economic: Growing healthcare expenditure and demand for cost-effective and timely diagnosis is fueling the market growth.
Social: Increasing incidence of infectious diseases and growing awareness about antimicrobial resistance is driving the demand for AST.
Technological: Introduction of innovative automated testing platforms with advanced features like higher throughput and shorter turnaround time is positively impacting the market.
Key Takeaways
The Global Antimicrobial Susceptibility Testing Market Growth is expected to witness high, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of infectious diseases. The market size for 2023 is US$ 3751.4 Mn.
Regional analysis: North America dominates the global AST market accounting for more than 35% share owing to technological advancements and presence of key players in the region. Asia Pacific is anticipated to witness fastest growth due to growing patient population, improving healthcare infrastructure, and increasing R&D initiatives in countries like India and China.
Key players operating in the antimicrobial susceptibility testing market are Thermo Fisher Scientific Inc., BIOMÉRIEUX, HiMedia Laboratories, Alifax S.r.l. Italy, Creative Diagnostics, Resistell AG, Danaher, Becton, Dickinson and Company, Merck KGaA, Bio-Rad Laboratories, Inc., Bruker, Nissui Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd.,Synbiosis, Mast Group Ltd., ELITechGroup, Flinn Scientific, CONDALAB, Accelerate Diagnostics, Inc. and Zhuhai DL Biotech Co., Ltd. Key players are focused on launching innovative automated systems with advanced features to consolidate their market position.